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Letter to the editor: response to Rogers et al. 2017 DOI: 10.3171/2016.11.JNS161170 
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Rogers et al. report the findings from the Intermediate-risk meningioma: initial outcomes 
from NRG Oncology RTOG 0539 study.7  Intermediate risk meningiomas were defined as 
those with a higher recurrence rate and includes gross total resection (GTR) WHO grade II 
meningioma (Simpson 1-3) and any recurrent WHO grade I meningioma regardless of the 
extent of resection. Despite the relative radioresistance of meningiomas, radiotherapy 
remains the only available adjuvant therapy for these tumors and in WHO grade II 
meningioma there is a lack of class I evidence for the role of early adjuvant radiotherapy.5 
Treatment decisions (i.e. adjuvant radiotherapy vs. no adjuvant radiotherapy) after surgery 
currently factor in tumor location, patient’s pre-treatment characteristics and the willingness 
of the surgeon to re-operate if recurrence occurs.4  Tumor recurrence undoubtedly has an 
impact on patient quality of life and if adjuvant radiotherapy can deliver prolonged control 
with low risk it should be considered in the multi-modality management of WHO grade II 
meningioma.  RTOG 0539 was a phase II non-randomised study with a primary endpoint of 
3-year progression free survival and included 36 patients with GTR grade II meningioma  
who received post-operative radiotherapy of which 1 patient progressed and 1 patient died of 
disease resulting in a 3 year local failure rate of 4.1%.  It is reassuring to note that the early 
adverse events (AE) from radiotherapy were limited to CTCAE grade 1 or 2 (mainly 
dermatological) with no severe events.  Neurosurgeons have been historically sceptical about 
adjuvant radiotherapy citing concerns about the risk of late cognitive decline and this is also a 
concern for patients.8  It is also reassuring that the RTOG 0539 study reported that mild 
memory decline affected only a small number of patients although detailed cognitive 
assessment was not performed. Likewise, another phase II trial performed by the European 
Organisation for the Research and Treatment of Cancer (EORTC 22042-26042) submitted for 
publication did not show any cognitive impact after high-dose radiotherapy and similar 
control rates (Damien C. Weber, personal communication; submitted for publication). The 
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relatively mild adverse events may be attributable to better radiotherapy planning techniques 
that minimise the radiotherapy dose to normal brain1 however it is important to emphasis that 
both phase II studies only had only 3 years follow-up and later meningioma recurrence may 
occur. The lack of a control arm is the main limitation of the study and neurosurgeons are 
likely to remain sceptical about adjuvant radiotherapy in GTR WHO grade II meningioma.  
Nevertheless, the favorable AE profile of radiotherapy supports the continued enrolment into 
open phase III studies.  The ROAM/EORTC 1308 trial [ISRCTN71502099] (Radiation 
versus Observation following surgical resection of Atypical Meningioma) is a multi-centre, 
phase III, randomised controlled trial (RCT) that will answer the question ‘in patients who 
have undergone gross total resection of atypical meningioma, does early adjuvant 
radiotherapy reduce recurrence compared to active monitoring?’3  The study is open across 
the UK, Europe, Australia and New Zealand (http://roam-trial.org.uk) with 44 sites open (63 
planned) and 36 patients randomised (190 planned).  The study is powered to detect an 
absolute reduction in recurrence rate from 40% (control arm) to 20% (radiotherapy arm)  at 5 
years and importantly will collect data on quality of life, neurocognitive function and assess 
whether adjuvant radiotherapy is cost-effective.  Studies of intervention versus monitoring 
can pose a recruitment challenge since clinicians and patients often exhibit bias .2,6 
Preliminary results from the embedded qualitative research study of audio recordings of the 
recruitment consultation have led to improvements by researchers in balancing the treatment 
arms and explaining equipoise.  In parallel the NRG BN-003 study 
(http://clinicaltrials.gov/ct2/show/NCT03180268) will also provide class I evidence.  It is 
incumbent on the neurosurgery and oncology community to work collaboratively to ensure 
both trials are successfully delivered in order to establish the best way to manage patients 
with complete resection of WHO grade II meningioma. 
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